Corin exploits orthopaedic niche, playing to informed market group
This article was originally published in Clinica
Orthopaedic implant developer Corin has developed a niche for itself in targeting the young, active population with hip and knee products that are more usually seen as the province of the older patient. And chairman and founder Peter Gibson told Clinica why he does not feel overpowered in the company of the industry's big hitters. Ashley Yeo reports
You may also be interested in...
The Personal Touch: Ortho Implants Challenger Corin Creates Its Own Value Pathway
Mid-size orthopedic implants group Corin is back in the public eye after its recent purchase by a Permira-funded group. Now ready to embark on the next chapter of its development globally, it has a clear growth plan and a firm strategic line on both what it will and will not do as a business.
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?